<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="94140">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01977755</url>
  </required_header>
  <id_info>
    <org_study_id>13-031</org_study_id>
    <nct_id>NCT01977755</nct_id>
  </id_info>
  <brief_title>Phase 2 Clinical Proof-of-Concept Study of the Cardioprotective Properties of Danegaptide in ST Segment Elevation Myocardial Infarction</brief_title>
  <official_title>A Randomised, Double-Blind, Placebo-Controlled, Parallel-Group Trial to Assess Clinical Efficacy and Safety of Danegaptide in Patients With ST-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zealand Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zealand Pharma</source>
  <oversight_info>
    <authority>Denmark: Ethics Committee</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study explores the potential cardioprotective properties of danegaptide when
      administered to patients with ST-Segment elevation myocardial infarction.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2013</start_date>
  <primary_completion_date type="Anticipated">May 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Myocardial Salvage Index</measure>
    <time_frame>3 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Myocardial Salvage Index as assessed by MRI and calculated as the difference between myocardial volume at risk and final infarct size in relation to myocardial volume at risk</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Relative Infarct size, Absolute Infarct size, Left Ventricular Ejection Fraction (LVEF), microvascular obstruction and infarct haemorrhage as determined by MRI</measure>
    <time_frame>3 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Degree of ST-resolution and fraction of patients with 70 % ST-resolution measured by ECG 60 minutes post Percutaneous Coronary Intervention procedure</measure>
    <time_frame>60 minutes</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major Clinical Adverse Events including cardiac death, new or worsening heart failure and re-admission for heart failure</measure>
    <time_frame>3 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">600</enrollment>
  <condition>STEMI</condition>
  <arm_group>
    <arm_group_label>danegapetide high dose</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>7,5 mg bolus injection, followed by 22,5 mg infused over 6 hours</description>
  </arm_group>
  <arm_group>
    <arm_group_label>danegaptide low dose</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>2,5 mg bolus injection, followed by 7,5 mg infused over 6 hours</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>bolus injection, followed by infused over 6 hours</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>danegaptide</intervention_name>
    <arm_group_label>danegapetide high dose</arm_group_label>
    <arm_group_label>danegaptide low dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age â‰¥ 18 years

          -  ST-segment elevation myocardial infarction

          -  Acute onset of chest pain of &lt; 12 hours duration

        Exclusion Criteria:

          -  Pregnancy

          -  Known prior Myocardial Infarction in same area as present STEMI, known hypertrophic
             or dilated cardiomyopathy, or prior  hospital admission for heart failure

          -  Contraindication for cardiac MRI

          -  Inability to understand information or provide informed consent
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas Engstrom, MD, DMSci</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Heart Center, Rigshopitalet University of Copenhagen</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Thomas Engstrom, MD, DMSci</last_name>
    <phone>004535458444</phone>
    <email>thomas.engstrom@rh.regionh.dk</email>
  </overall_contact>
  <location>
    <facility>
      <name>The Heart Center, Rigshospitalet, University of Copenhagen</name>
      <address>
        <city>Copenhagen</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas Engstrom, MD, DMSci</last_name>
      <phone>004535458444</phone>
      <email>thomas.engstrom@rh.regionh.dk</email>
    </contact>
    <investigator>
      <last_name>Thomas Engstrom, MD, DMSci</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>November 2013</verification_date>
  <lastchanged_date>November 27, 2013</lastchanged_date>
  <firstreceived_date>October 30, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
